Anbio Financial Statements From 2010 to 2026

NNNN Stock   24.47  0.15  0.61%   
Anbio Biotechnology's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Anbio Biotechnology's valuation are provided below:
Gross Profit
6.2 M
Profit Margin
0.372
Market Capitalization
1.1 B
Enterprise Value Revenue
134.7655
Revenue
6.9 M
We have found one hundred one available fundamental signals for Anbio Biotechnology Class, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Anbio Biotechnology's prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 26th of February 2026, Enterprise Value is likely to drop to about 253.7 M

Anbio Biotechnology Total Revenue

8.57 Million

Check Anbio Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anbio Biotechnology's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 407.5 K or Interest Income of 407.5 K, as well as many indicators such as Price To Sales Ratio of 32.57, Dividend Yield of 0.0 or PTB Ratio of 15.51. Anbio financial statements analysis is a perfect complement when working with Anbio Biotechnology Valuation or Volatility modules.
  
Build AI portfolio with Anbio Stock
Check out the analysis of Anbio Biotechnology Correlation against competitors.

Anbio Biotechnology Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets14.7 M21.8 M8.5 M
Slightly volatile
Total Current Liabilities1.3 M1.6 M2.1 M
Slightly volatile
Total Stockholder Equity13 M19.8 M6.3 M
Slightly volatile
Current Deferred Revenue392 K441 K481.4 K
Slightly volatile
Retained Earnings12.9 M19.7 M6.3 M
Slightly volatile
Accounts Payable1.2 M1.5 M1.7 M
Slightly volatile
CashM13.5 MM
Slightly volatile
Cash And Short Term Investments9.4 M13.5 M6.1 M
Slightly volatile
Net ReceivablesM1.2 M811.6 K
Slightly volatile
Common Stock Shares Outstanding36.2 M38.1 M97 M
Pretty Stable
Liabilities And Stockholders Equity14.7 M21.8 M8.5 M
Slightly volatile
Other Current Assets4.1 M6.6 M1.5 M
Slightly volatile
Total Liabilities1.3 M1.6 M2.1 M
Slightly volatile
Net Invested Capital13 M19.8 M6.3 M
Slightly volatile
Total Current Assets14.6 M21.3 M8.4 M
Slightly volatile
Net Working Capital12.8 M19.3 M6.3 M
Slightly volatile
Other Current Liabilities100.5 K120.7 K31.4 K
Slightly volatile
Non Currrent Assets Other467.8 K445.6 K82.5 K
Slightly volatile
Other Stockholder EquityK3.4 K3.7 K
Slightly volatile
Common Stock11.4 K12.8 K14 K
Slightly volatile

Anbio Biotechnology Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative4.1 MM941.3 K
Slightly volatile
Total Revenue8.6 M7.4 M6.3 M
Slightly volatile
Gross Profit6.7 M6.8 M3.9 M
Slightly volatile
Other Operating Expenses7.2 M7.1 M3.7 M
Slightly volatile
Operating Income3.3 M1.8 M2.9 M
Pretty Stable
Net Income From Continuing Ops3.4 M2.1 MM
Pretty Stable
EBIT3.3 M1.8 M2.9 M
Pretty Stable
EBITDA3.5 M2.3 MM
Pretty Stable
Cost Of Revenue3.7 M2.1 M2.6 M
Slightly volatile
Total Operating Expenses4.7 M4.5 M1.1 M
Slightly volatile
Income Before Tax3.4 M2.1 MM
Pretty Stable
Net Income3.4 M2.1 MM
Pretty Stable
Depreciation And Amortization10.6 K15 K7.8 K
Slightly volatile

Anbio Biotechnology Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Change In Cash2.4 M1.9 M3.6 M
Slightly volatile
Free Cash Flow2.3 M1.9 M3.6 M
Slightly volatile
Total Cash From Operating Activities2.3 M1.9 M3.6 M
Slightly volatile
Net Income3.4 M2.1 MM
Pretty Stable
End Period Cash FlowM13.5 MM
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio32.5734.28107
Slightly volatile
PTB Ratio15.5116.32171
Slightly volatile
Days Sales Outstanding41.8342.7355.5441
Pretty Stable
Book Value Per Share0.380.370.0971
Slightly volatile
Free Cash Flow Yield0.00610.00980.0069
Pretty Stable
Operating Cash Flow Per Share0.03520.05660.04
Pretty Stable
Average Payables894.1 KM1.1 M
Slightly volatile
Capex To Depreciation4.0E-44.0E-45.0E-4
Slightly volatile
PB Ratio15.5116.32171
Slightly volatile
EV To Sales31.032.63106
Slightly volatile
Free Cash Flow Per Share0.03520.05660.04
Pretty Stable
ROIC0.130.11610.7613
Slightly volatile
Inventory Turnover24.8227.9330.4828
Slightly volatile
Net Income Per Share0.03340.05050.0311
Slightly volatile
Days Of Inventory On Hand9.4110.5911.5552
Slightly volatile
Payables Turnover1.551.631.672
Slightly volatile
Research And Ddevelopement To Revenue0.05240.04990.017
Slightly volatile
Cash Per Share0.260.250.0834
Slightly volatile
POCF Ratio100106182
Pretty Stable
Interest CoverageK1.1 K1.3 K
Slightly volatile
Capex To Operating Cash Flow0.00.00.0
Slightly volatile
PFCF Ratio100106182
Pretty Stable
Days Payables Outstanding209297311
Slightly volatile
Income Quality0.921.011.3786
Slightly volatile
ROE0.150.160.6455
Slightly volatile
EV To Operating Cash Flow95.45100179
Pretty Stable
PE Ratio215118213
Slightly volatile
Return On Tangible Assets0.140.12540.4386
Slightly volatile
EV To Free Cash Flow95.45100179
Pretty Stable
Earnings Yield0.00580.00880.0054
Slightly volatile
Current Ratio7.79.644.6222
Slightly volatile
Tangible Book Value Per Share0.380.370.0971
Slightly volatile
Receivables Turnover8.48.84393
Pretty Stable
Graham Number0.680.640.2376
Slightly volatile
Shareholders Equity Per Share0.380.370.0971
Slightly volatile
Graham Net Net0.240.230.0664
Slightly volatile
Average Receivables521.9 K849.8 K467.5 K
Slightly volatile
Revenue Per Share0.0880.170.0702
Slightly volatile
Interest Debt Per Share0.01.0E-41.0E-4
Slightly volatile
Enterprise Value Over EBITDA98.86104203
Slightly volatile
Price Earnings Ratio215118213
Slightly volatile
Operating Cycle44.1942.7356.3748
Pretty Stable
Price Book Value Ratio15.5116.32171
Slightly volatile
Days Of Payables Outstanding209297311
Slightly volatile
Price To Operating Cash Flows Ratio100106182
Pretty Stable
Price To Free Cash Flows Ratio100106182
Pretty Stable
Pretax Profit Margin0.450.330.5119
Slightly volatile
Ebt Per Ebit0.871.071.0383
Very volatile
Operating Profit Margin0.420.280.4896
Slightly volatile
Company Equity Multiplier1.431.271.7201
Slightly volatile
Return On Capital Employed0.130.11610.7613
Slightly volatile
Ebit Per Revenue0.420.280.4896
Slightly volatile
Quick Ratio7.669.644.6051
Slightly volatile
Dividend Paid And Capex Coverage Ratio1.2 M1.4 M1.5 M
Slightly volatile
Cash Ratio4.676.123.1446
Slightly volatile
Operating Cash Flow Sales Ratio0.420.290.7422
Slightly volatile
Days Of Inventory Outstanding9.4110.5911.5552
Slightly volatile
Days Of Sales Outstanding41.8342.7355.5441
Pretty Stable
Price To Book Ratio15.5116.32171
Slightly volatile
Fixed Asset Turnover1.6 K1.8 K1.9 K
Slightly volatile
Capital Expenditure Coverage Ratio1.2 M1.4 M1.5 M
Slightly volatile
Price Cash Flow Ratio100106182
Pretty Stable
Enterprise Value Multiple98.86104203
Slightly volatile
Price Sales Ratio32.5734.28107
Slightly volatile
Return On Assets0.140.12540.4386
Slightly volatile
Asset Turnover0.950.50.8709
Pretty Stable
Net Profit Margin0.450.330.5119
Slightly volatile
Gross Profit Margin0.460.650.5736
Very volatile
Price Fair Value15.5116.32171
Slightly volatile
Return On Equity0.150.160.6455
Slightly volatile

Anbio Biotechnology Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap266.6 M280.6 M730.3 M
Slightly volatile
Enterprise Value253.7 M267.1 M722 M
Slightly volatile

Anbio Fundamental Market Drivers

About Anbio Biotechnology Financial Statements

Anbio Biotechnology investors utilize fundamental indicators, such as revenue or net income, to predict how Anbio Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue441 K392 K
Total Revenue7.4 M8.6 M
Cost Of Revenue2.1 M3.7 M
Research And Ddevelopement To Revenue 0.05  0.05 
Revenue Per Share 0.17  0.09 
Ebit Per Revenue 0.28  0.42 

Pair Trading with Anbio Biotechnology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Anbio Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Anbio Biotechnology will appreciate offsetting losses from the drop in the long position's value.

Moving against Anbio Stock

  0.63CMB Cambium BioPairCorr
  0.48DNTH Dianthus TherapeuticsPairCorr
  0.47DNLI Denali Therapeutics Earnings Call This WeekPairCorr
  0.382CG NANOSPHERE HEASCIENCESPairCorr
  0.35ALSEN Sensorion SAPairCorr
The ability to find closely correlated positions to Anbio Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Anbio Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Anbio Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Anbio Biotechnology Class to buy it.
The correlation of Anbio Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Anbio Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Anbio Biotechnology Class moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Anbio Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Anbio Biotechnology Class offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Anbio Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anbio Biotechnology Class Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anbio Biotechnology Class Stock:
Check out the analysis of Anbio Biotechnology Correlation against competitors.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Biotechnology sector continue expanding? Could Anbio diversify its offerings? Factors like these will boost the valuation of Anbio Biotechnology. Anticipated expansion of Anbio directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Anbio Biotechnology data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
0.028
Earnings Share
0.06
Revenue Per Share
0.161
Quarterly Revenue Growth
(0.22)
Return On Assets
0.0473
Understanding Anbio Biotechnology Class requires distinguishing between market price and book value, where the latter reflects Anbio's accounting equity. The concept of intrinsic value - what Anbio Biotechnology's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Anbio Biotechnology's price substantially above or below its fundamental value.
It's important to distinguish between Anbio Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Anbio Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Anbio Biotechnology's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.